Positive Ph III results from Sanofi GetGoal Program on Lyxumia

French drug major Sanofi (Euronext: SAN) announced today that new results from a Phase III study showed that the investigational product Lyxumia (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia.

GetGoal-L is one of nine studies in the GetGoal Phase III clinical program, and the second trial to investigate the benefits of lixisenatide 20mcg once-daily combined with basal insulin. It was a randomized (double-blind), placebo-controlled study with a 24-week main treatment period, and a total of 495 patients received either lixisenatide or placebo.

Sanofi licensed lixisenatide from Denmark’s Zealand Pharma and the glucagon-like peptide-1 agonist (GLP-1) treatment is seen as a possible blockbuster which could help Sanofi reach its goal of becoming the world's top diabetes treatment company.